Current Report Filing (8-k)
March 28 2017 - 8:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): March 28,
2017
CORD BLOOD AMERICA, INC.
(Exact name of registrant as specified in its
charter)
Florida
|
|
000-50746
|
|
90-0613888
|
(State
or Other Jurisdiction
|
|
(Commission
|
|
(I.R.S.
Employer
|
of
Incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
1857 Helm Drive, Las Vegas, NV 89119
(Address of Principal Executive Office) (Zip
Code)
(702) 914-7250
(Registrant’s telephone number, including area
code)
_______________________________
Copies to:
Stephen Morgan
1857 Helm Drive, Las Vegas, NV 89119
Phone: (702) 914-7250
Fax: (702) 914-7251
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02
Results of Operations and Financial Condition.
On March 28, 2016, Cord Blood America, Inc. (the
“Company”) issued the Press Release attached as Exhibit
99.1 to this report. The Press Release provides details related to
the Company’s financial results and earnings for the fiscal
year ended December 31, 2016 and the three months ended December
31, 2016.
The information furnished under this Item 2.02 on this Form
8-K, including Exhibit 99.1 attached hereto, shall not be deemed
“filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the
“
Exchange
Act
”), or otherwise
subject to the liabilities of that section, nor shall it be deemed
incorporated by reference into any other filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as
expressly set forth by specific reference in such a
filing.
Item 7.01 Regulation FD Disclosure.
The Press Release attached as Exhibit 99.1 to this report announced
that after a
lengthy strategic review process, the Board was
unable to execute a sale of the business. The Board, in
consultation with the Company’s financial advisor, Boxwood
Partners, LLC, made the decision to discontinue sale talks with
bidders after having been engaged in negotiations for a lengthy
period of time. The Company continues to have high level
discussions regarding mergers and acquiring other related
businesses that may have high cash synergies without increased
complexity.
A copy of the Press
Release is furnished as Exhibit 99.1 to this Current Report on Form
8-K and incorporated by reference in this
Item 7.01.
The information furnished under this Item 7.01 on this Form
8-K, including Exhibit 99.1 attached hereto, shall not be deemed
“filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended
, or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference into any
other filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits
The following Exhibits are furnished herewith:
|
Press
Release dated March 28, 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly
authorized.
|
CORD BLOOD AMERICA, INC.
|
|
|
|
(Registrant)
|
|
|
|
|
|
Date:
March 28, 2017
|
By:
|
/s/Stephen
Morgan
|
|
|
|
Interim
President
|
|